138 related articles for article (PubMed ID: 19949039)
1. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Sherman JH; Aregawi DG; Lai A; Fathallah-Shaykh HM; Bierman PJ; Linsky K; Larner JM; Newman SA; Schiff D
Neurology; 2009 Dec; 73(22):1924-6. PubMed ID: 19949039
[No Abstract] [Full Text] [Related]
2. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Chamberlain MC; Raizer J; Schiff D; Sherman JH
Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
[No Abstract] [Full Text] [Related]
3. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.
Keenan BP; Abuav R
Arch Dermatol; 2010 May; 146(5):577. PubMed ID: 20479324
[No Abstract] [Full Text] [Related]
4. Ipilimumab and Bevacizumab in Glioblastoma.
Carter T; Shaw H; Cohn-Brown D; Chester K; Mulholland P
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):622-626. PubMed ID: 27169593
[TBL] [Abstract][Full Text] [Related]
5. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
Henriksson R; Bergström P; Johansson M; Sandström M
Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
[No Abstract] [Full Text] [Related]
6. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
Wilkes GM
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
[No Abstract] [Full Text] [Related]
7. Bevacizumab antiangiogenic therapy for glioblastoma.
Junck L
Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
[No Abstract] [Full Text] [Related]
8. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
[No Abstract] [Full Text] [Related]
9. Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.
Lomax AJ; Yannakou CK; Rosenthal MA
Target Oncol; 2013 Jun; 8(2):153-5. PubMed ID: 23430346
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
[TBL] [Abstract][Full Text] [Related]
11. First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?
Marosi C
CNS Oncol; 2013 Nov; 2(6):473-4. PubMed ID: 25054815
[No Abstract] [Full Text] [Related]
12. Bevacizumab therapy for glioblastoma: a passionate discussion.
Desjardins A; Friedman HS
CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
[No Abstract] [Full Text] [Related]
13. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
Stupp R; Weller M
Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
[No Abstract] [Full Text] [Related]
14. Bevacizumab in glioblastoma--still much to learn.
Fine HA
N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
[No Abstract] [Full Text] [Related]
15. Management of a complex scalp defect.
Plast Reconstr Surg; 2008 Aug; 122(2):623-625. PubMed ID: 18626384
[No Abstract] [Full Text] [Related]
16. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
18. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
20. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
